AngioDynamics, Inc. (NASDAQ:ANGO) Short Interest Update

AngioDynamics, Inc. (NASDAQ:ANGO) was the recipient of a significant decrease in short interest during the month of January. As of January 15th, there was short interest totalling 882,000 shares, a decrease of 11.8% from the December 31st total of 1,000,000 shares. Based on an average daily trading volume, of 625,200 shares, the days-to-cover ratio is presently 1.4 days.

Insiders Place Their Bets

In other news, SVP Warren Nighan, Jr. sold 4,060 shares of the business’s stock in a transaction that occurred on Thursday, January 16th. The stock was sold at an average price of $12.31, for a total value of $49,978.60. Following the transaction, the senior vice president now directly owns 41,817 shares of the company’s stock, valued at $514,767.27. The trade was a 8.85 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Insiders own 5.40% of the company’s stock.

Institutional Trading of AngioDynamics

Several institutional investors and hedge funds have recently made changes to their positions in the business. Segall Bryant & Hamill LLC boosted its position in shares of AngioDynamics by 142.7% in the 3rd quarter. Segall Bryant & Hamill LLC now owns 911,443 shares of the medical instruments supplier’s stock worth $7,091,000 after purchasing an additional 535,958 shares during the last quarter. Millennium Management LLC grew its position in shares of AngioDynamics by 41.9% during the 2nd quarter. Millennium Management LLC now owns 1,793,454 shares of the medical instruments supplier’s stock worth $10,850,000 after buying an additional 529,861 shares during the period. Systematic Financial Management LP increased its stake in shares of AngioDynamics by 14.3% in the 3rd quarter. Systematic Financial Management LP now owns 2,410,346 shares of the medical instruments supplier’s stock valued at $18,752,000 after acquiring an additional 300,785 shares during the last quarter. JPMorgan Chase & Co. raised its position in shares of AngioDynamics by 28.7% in the 3rd quarter. JPMorgan Chase & Co. now owns 553,161 shares of the medical instruments supplier’s stock valued at $4,304,000 after acquiring an additional 123,271 shares during the period. Finally, Royce & Associates LP boosted its stake in AngioDynamics by 10.8% during the 3rd quarter. Royce & Associates LP now owns 986,073 shares of the medical instruments supplier’s stock worth $7,672,000 after acquiring an additional 96,138 shares during the last quarter. Institutional investors own 89.43% of the company’s stock.

AngioDynamics Price Performance

Shares of ANGO stock traded down $1.05 on Friday, reaching $11.41. 1,313,187 shares of the stock were exchanged, compared to its average volume of 948,057. AngioDynamics has a one year low of $5.26 and a one year high of $13.50. The stock has a market cap of $461.76 million, a PE ratio of -2.03 and a beta of 0.59. The stock has a 50 day moving average price of $9.81 and a 200 day moving average price of $8.10.

AngioDynamics (NASDAQ:ANGO) last released its earnings results on Wednesday, January 8th. The medical instruments supplier reported ($0.04) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.11) by $0.07. AngioDynamics had a negative net margin of 79.38% and a negative return on equity of 7.26%. The company had revenue of $72.90 million for the quarter, compared to the consensus estimate of $70.93 million. During the same period in the prior year, the company posted ($0.05) EPS. The company’s revenue was down .1% compared to the same quarter last year. On average, research analysts expect that AngioDynamics will post -0.37 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

ANGO has been the topic of several research analyst reports. HC Wainwright increased their target price on AngioDynamics from $14.00 to $15.00 and gave the stock a “buy” rating in a report on Friday, January 10th. Canaccord Genuity Group dropped their target price on shares of AngioDynamics from $13.00 to $12.00 and set a “buy” rating for the company in a research note on Friday, October 4th.

About AngioDynamics

AngioDynamics, Inc, a medical technology company, engages in the design, manufacture, and sale of medical, surgical, and diagnostic devices for the use in treating peripheral vascular disease, and oncology and surgical settings in the United States and internationally. The company offers Auryon Atherectomy system that is designed to deliver an optimized wavelength, pulse width, and amplitude to remove lesions while preserving vessel wall endothelium.